Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
EVGN 
Evogene (EVGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EVGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.53% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.85M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 2 | Beta 1.42 | 52 Weeks Range 0.95 - 4.17 | Updated Date 08/15/2025 |
52 Weeks Range 0.95 - 4.17 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.51 |
Earnings Date
Report Date 2025-08-19 | When - | Estimate -0.605 | Actual - |
Profitability
Profit Margin -224.82% | Operating Margin (TTM) -168.82% |
Management Effectiveness
Return on Assets (TTM) -35.1% | Return on Equity (TTM) -91.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14344636 | Price to Sales(TTM) 1.75 |
Enterprise Value 14344636 | Price to Sales(TTM) 1.75 | ||
Enterprise Value to Revenue 2.12 | Enterprise Value to EBITDA -0.81 | Shares Outstanding 8714230 | Shares Floating 6606385 |
Shares Outstanding 8714230 | Shares Floating 6606385 | ||
Percent Insiders 0.96 | Percent Institutions 5.21 |
Upturn AI SWOT
Evogene
Company Overview
History and Background
Evogene Ltd. was founded in 2002 in Israel. It is a computational biology company focused on revolutionizing product discovery and development in life-science industries, including agriculture, healthcare, and industrial applications.
Core Business Areas
- Agriculture: Utilizes computational biology to discover and develop improved seeds and traits for crop enhancement, focusing on yield, biotic stress resistance (e.g., insect and disease resistance), and abiotic stress tolerance (e.g., drought tolerance).
- Human Health: Leverages its computational biology platform to identify and develop novel therapeutic candidates, primarily focusing on microbiome-based solutions and precision medicine.
- Industrial: Applies its technology to enhance the production efficiency of industrial enzymes and other biological compounds.
Leadership and Structure
The leadership team consists of experienced scientists, business executives, and board members. The organizational structure is typically divided into research and development, business development, and operations, with specific teams dedicated to each core business area.
Top Products and Market Share
Key Offerings
- Insect Resistance Traits: Develops insect resistance traits for crops, particularly corn and soybean. While specific market share is difficult to determine due to licensing agreements, they target the global insect resistance market, which is dominated by major players like Bayer and Corteva. Competitors include Bayer, Corteva, Syngenta.
- Microbiome-based Therapeutics: Focuses on developing microbiome-based therapeutics for inflammatory bowel disease (IBD) and other indications through its subsidiaries. Market share is currently minimal as products are in clinical development. Competitors include Seres Therapeutics, Finch Therapeutics.
- Seed Enhancement: Enhancement of seeds that provide improved yield and resistance to weather change.
Market Dynamics
Industry Overview
The agriculture industry is experiencing a growing demand for sustainable and high-yielding crop solutions due to population growth and climate change. The human health industry is seeing increased interest in microbiome-based therapies and precision medicine. The industrial biotechnology sector seeks efficient and sustainable production methods.
Positioning
Evogene positions itself as an innovator in computational biology-driven product development, aiming to improve the efficiency and effectiveness of discovery processes in agriculture, human health, and industrial applications. Its competitive advantage lies in its computational biology platform, which allows it to identify promising biological targets and develop novel solutions more quickly and efficiently than traditional methods.
Total Addressable Market (TAM)
The TAM across Evogene's target markets (agriculture, human health, industrial biotech) is estimated to be in the hundreds of billions of USD. Evogene is positioned to capture a share of this market through its innovative technologies and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary computational biology platform
- Strong R&D capabilities
- Diversified business areas (agriculture, healthcare, industrial)
- Strategic partnerships with leading companies
Weaknesses
- Limited commercialized products
- Dependence on partnerships for revenue
- High R&D expenses
- Relatively small market capitalization
Opportunities
- Growing demand for sustainable agriculture solutions
- Increasing interest in microbiome-based therapies
- Potential for strategic acquisitions and partnerships
- Expansion into new markets and applications
Threats
- Competition from larger, established players
- Regulatory hurdles for new products
- Intellectual property risks
- Economic downturns
Competitors and Market Share
Key Competitors
- BAYRY (Bayer)
- DD (Corteva)
- SYT (Syngenta, acquired by ChemChina)
Competitive Landscape
Evogene is a smaller player compared to major agricultural and pharmaceutical companies. Its competitive advantage lies in its computational biology platform, but it faces challenges in commercializing products and competing with larger companies' resources.
Major Acquisitions
AgPlenus Ltd.
- Year: 2019
- Acquisition Price (USD millions): 14.5
- Strategic Rationale: To expand Evogene's crop protection capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are reflected in past revenue, which must be found in financial reports.
Future Projections: Future growth projections depend on various factors, including product development success, market adoption, and strategic partnerships. Analyst estimates should be monitored.
Recent Initiatives: Recent initiatives include strategic partnerships, expansion of product pipelines, and investment in new technologies.
Summary
Evogene is a computational biology company targeting agriculture, healthcare, and industrial sectors. The companyu2019s strength is in its technology platform and R&D, however, it needs to commercialize its products more effectively. Evogene faces strong competition from larger companies and regulatory hurdles. Successful partnerships and market adoption are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evogene
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2008-03-05 | CEO, President & Director Mr. Ofer Haviv CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 117 | Website https://www.evogene.com |
Full time employees 117 | Website https://www.evogene.com | ||
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.